{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:02:32Z","timestamp":1787770952626,"version":"build-2784847793"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to explore and analyze the various causes, clinical features, and prognostic differences of secondary hemophagocytic syndrome (SHS) in children in Gansu Province, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study used a retrospective analysis method, selected 43 children with HLH who were treated in the PICU at the First Hospital of Lanzhou University from January 2019 to January 2025. Based on their primary diseases, the subjects were categorized into groups for VL, EB virus infection, and other infections. The clinical manifestations, laboratory results and clinical outcomes of each group were comprehensively analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The main cause of HLH was infection (35\/43 cases), with EB virus infection (15\/35 cases) and leishmania (13\/35 cases) being the most common. In the leishmania and EB virus infection group, the average of alanine aminotransferase (ALT) levels were 81\u2005U\/L and 87\u2005U\/L respectively, were higher than other infection group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u2009\n                      <jats:italic>0.05<\/jats:italic>\n                      ). The average of procalcitonin (PCT) levels were 2.88\u2005ng\/mL, 4.37\u2005ng\/mL respectively in the Leishmania group and other infection group, were higher than EBV infection group(0.43\u2005ng\/mL). The average of D-dimer (D-D) levels were statistically significant differences among Leishmania group(2.31\u2005mg\/dL), EBV infection group(2.12\u2005mg\/dL) and the other infection group (3.34\u2005ng\/mL). The leishmania group had a cure rate of 100% (13\/13), while the EB virus infection group had a cure rate of 26.67% (4\/15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Leishmania and EB virus infection are common causes of HLH in Gansu Province. Compared to HLH caused by other factors such as EB virus infection or autoimmune diseases, the prognosis of HLH in children with leishmania infection is relatively better.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1660880","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:36:49Z","timestamp":1762429009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical analysis of secondary hemophagocytic syndrome in children in Gansu province"],"prefix":"10.3389","volume":"13","author":[{"given":"Yongkang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3760\/cma.j.cn112137-20220310-00488","article-title":"\u4e2d\u56fd\u566c\u8840\u7ec6\u80de\u7efc\u5408\u5f81\u8bca\u65ad\u4e0e\u6cbb\u7597\u6307\u5357 (2022\u5e74\u7248)","volume":"102","year":"2022","journal-title":"\u4e2d\u534e\u533b\u5b66\u6742\u5fd7"},{"key":"B2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.11768\/nkjwzzzz20250203","article-title":"\u566c\u8840\u7ec6\u80de\u7efc\u5408\u5f81\u7684\u8bca\u7597\u8fdb\u5c55","volume":"31","author":"\u738b\u6676\u77f3","year":"2025","journal-title":"\u5185\u79d1\u6025\u5371\u91cd\u75c7\u6742\u5fd7"},{"key":"B3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3969\/j.issn.1673-5625.2015.05.028","article-title":"\u7518\u8083\u7701\u4e09\u7ea7\u7532\u7b49\u533b\u9662\u75be\u75c5\u8c31\u6d41\u884c\u75c5\u5b66\u5206\u6790\u4e0e\u6162\u6027\u75c5\u9632\u6cbb\u7b56\u7565","volume":"32","author":"\u5218\u7231\u751f","year":"2015","journal-title":"\u4e2d\u56fd\u793e\u4f1a\u533b\u5b66\u6742\u5fd7"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.13604\/j.cnki.46-1064\/r.2022.01.02","article-title":"\u7518\u8083\u7701\u6587\u53bf, \u8fed\u90e8\u53bf\u5bb6\u72ac\u611f\u67d3\u5229\u4ec0\u66fc\u539f\u866b\u5371\u9669\u56e0\u7d20\u7814\u7a76","volume":"22","author":"\u4f59\u5927\u4e3a","year":"2022","journal-title":"\u4e2d\u56fd\u70ed\u5e26\u533b\u5b66"},{"key":"B5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3969\/j.issn.1004-583X.2015.03.020","article-title":"\u9ed1\u70ed\u75c579\u4f8b\u4e34\u5e8a\u8bca\u6cbb\u56de\u987e\u6027\u5206\u6790","volume":"30","author":"\u5218\u771f\u771f","year":"2015","journal-title":"\u4e34\u5e8a\u835f\u8403"},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American college of rheumatology\/paediatric rheumatology international trials organisation collaborative initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12519-019-00299-3","article-title":"Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children","volume":"16","author":"Xu","year":"2020","journal-title":"World J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ejh.14029","article-title":"Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review","volume":"111","author":"Charlesworth","year":"2023","journal-title":"Eur J Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14740\/wjon1464","article-title":"Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy","volume":"13","author":"Rajapakse","year":"2022","journal-title":"World J Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.51821\/88.1.13361","article-title":"An unusual case of acute cholestatic hepatitis: visceral leishmaniasis with secondary haemophagocytic lymphohistiocytosis","volume":"88","author":"Gestels","year":"2025","journal-title":"Acta Gastroenterol Belg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3760\/cma.j.issn.1000-6680.2017.10.001","article-title":"\u4e2d\u56fd\u5229\u4ec0\u66fc\u539f\u866b\u611f\u67d3\u8bca\u65ad\u548c\u6cbb\u7597\u4e13\u5bb6\u5171\u8bc6","volume":"35","year":"2017","journal-title":"\u4e2d\u534e\u4f20\u67d3\u75c5\u6742\u5fd7"},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/labmed\/lmac134","article-title":"Review of the clinical presentation, pathology, diagnosis, and treatment of leishmaniasis","volume":"54","author":"Mathison","year":"2023","journal-title":"Lab Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/ddg.15424","article-title":"Treatment of mucocutaneous leishmaniasis - A systematic review","volume":"22","author":"Fischer","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B16","volume-title":"EBV-Associated Myopericarditis","author":"Das","year":"2025"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-3-319-22822-8_15","article-title":"EBV And autoimmunity","volume":"390","author":"Ascherio","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072133","article-title":"EBV and lymphomagenesis","volume":"15","author":"Sausen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s13023-021-01976-1","article-title":"Epidemiological investigation of hemophagocytic lymphohistiocytosis in China","volume":"16","author":"Yao","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/00494755211038129","article-title":"Diverse liver morphology in two cases of visceral leishmaniasis: same face, different expressions","volume":"52","author":"Dhawan","year":"2022","journal-title":"Trop Doct"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1213\/ANE.0000000000006888","article-title":"Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies","volume":"138","author":"Williams","year":"2024","journal-title":"Anesth Analg"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1660880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:37:13Z","timestamp":1762429033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1660880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":22,"alternative-id":["10.3389\/fped.2025.1660880"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1660880","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1660880"}}